Teva's biosimilars play

Like several other small molecule generics companies, Teva Pharmaceutical Industries Ltd. has identified biopharmaceuticals as a key component of its long-term strategy. The company says last week's deal to acquire CoGenesys Inc. will help it become a player in biosimilars.

For its part, CoGenesys gets access to extensive clinical and regulatory experience to accelerate the commercialization of its research. ...